Novartis announced positive news for patients with metastatic breast cancer. New data showed Kisqali (ribociclib), in combination with the chemotherapy drug fulvestrant, added nearly 16 months of survival benefit to the lives of patients compared to fulvestrant alone.
Interim data from Roche Group member Genentech’s first randomized study of a candidate treatment for extensive-stage small cell lung cancer (ES-SCLC) failed to meet the clinical trial’s co-primary endpoint against the hard-to-treat disease.
New Jersey-based Eagle Pharmaceuticals, a company geared towards pharmaceutical hospital sales, finalized terms to acquire Acacia Pharma.
AstraZeneca said on March 24 the company’s drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening.
The U.S. Food and Drug Administration approved the expanded use of Bristol Myers Squibb’s cancer drug Opdivo along with chemotherapy as treatment that patients with an aggressive form of lung cancer receive before surgery.
Pivotal Phase 3 Data for Keytruda in High-Risk Early-Stage TNBC Published in the New England Journal of MedicineBlockbusters, Chemotherapy, Clinical Trials, Event-Free Survival (EFS), Keytruda, Neoadjuvant Chemoradiotherapy (CRT), New England Journal of Medicine, New Indications, R&D, Triple Negative Breast Cancer (TNBC)
Merck announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant Keytruda in combination with chemotherapy followed by adjuvant Keytruda as monotherapy, significantly prolonged event-free survival compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).
AstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens.
Novartis said on Oct. 25 the company’s canakinumab drug failed in another clinical trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.
A new study helps quantify the improved protection against Covid-19 achieved with a third booster dose of the vaccine from Pfizer Inc. and BioNTech SE in cancer patients who are undergoing chemotherapy.
Lung Cancer Breakthroughs Touted at ESMO 2021AstraZeneca, Clinical Data, Clinical Trials, Daiichi Sankyo, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Janssen, KRAS Mutations, Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-Based Chemotherapy, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Topline Data
Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.